Первая клетка. И чего стоит борьба с раком до последнего - Азра Раза
Шрифт:
Интервал:
Закладка:
Hoos A. Development of Immuno-Oncology Drugs – From CTLA4 to PD1 to the Next Generations. Nature Reviews Drug Discovery. 15, no. 4 (2016): 235–247.
Coulie P. G. et al. Tumour Antigens Recognized by T Lymphocytes: At the Core of Cancer Immunotherapy. Nature Reviews Cancer. 14, no. 2 (2014): 135–146.
Schmidt Ch. The Struggle to Do No Harm in Clinical Trials: What Lessons Are Being Learnt from Studies That Went Wrong? Nature, December 20, 2017. doi:10.1038/d41586-017-08705-4.
Maude S. L. et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine. 378, no. 5 (2018): 439–448.
Editorial. CAR T-Cell Therapy: Perceived Need Versus Actual Evidence. Lancet Oncology. 19, no. 10 (2018): 1259.
Osorio J. Cancer Immunotherapy Research Round-Up: Highlights from Clinical Trials. Nature, December 20, 2017.
Barreyro L. et al. Chronic Immune Response Dysregulation in MDS Pathogenesis. Blood. 132, no. 15 (2018): 1553–1560.
Almasbak H. et al. CAR T Cell Therapy: A Game Changer in Cancer Treatment. Journal of Immunology Research, 2016. doi:10.1155/2016/5474602.
Sun Sh. et al. Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies. Journal of Immunology Research, 2018. doi:10.1155/2018/2386187.
Doudna J. A., Sternberg S. H. A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution. Boston: Houghton Mifflin Harcourt, 2017. [Даудна Дж., Стернберг С. Трещина в мироздании. М.: Corpus, 2019.]
Haapaniemi E. et al. CRISPR – Cas9 Genome Editing Induces a p53-Mediated DNA Damage Response. Nature Medicine, 2018. doi:10.1038/s41591-018-0049-z.
Shin H. Y. et al. CRISPR/Cas9 Targeting Events Cause Complex Deletions and Insertions at 17 Sites in the Mouse Genome. Nature Communications. 8 (2017): article 15464.
Kosicki M. et al. Repair of Double-Strand Breaks Induced by CRISPR – Cas9 Leads to Large Deletions and Complex Rearrangements. Nature Biotechnology. 36 (2018): 765–771.
Глава 7. ХарвиWeir H. K. et al. The Past, Present, and Future of Cancer Incidence in the United States: 1975 Through 2020. Cancer. 121, no. 11 (2015): 1827–1837.
By the Numbers: NCI Budget Breakdown, FY 2018. doi:10.1158/2159–8290.CD-NB2019–002.
Aparicio S., Caldas C. The Implications of Clonal Genome Evolution for Cancer Medicine. New England Journal of Medicine. 368 (2013): 842–851.
Walter M. J. et al. Clonal Architecture of Secondary Acute Myeloid Leukemia. New England Journal of Medicine. 366 (2012): 1090–1098.
Ruiz C. et al. Advancing a Clinically Relevant Perspective of the Clonal Nature of Cancer. PNAS. 108 (2011): 12054–12059.
Cohen J. ‘It’s Sobering’: A Once-Exciting HIV Cure Strategy Fails Its Test in People. Science, July 25, 2018. doi:10.1126/science.aau8963.
Crowley E. et al. Liquid Biopsy: Monitoring Cancer-Genetics in the Blood. Nature Reviews Clinical Oncology. 10 (2013): 472–484.
Bleyer A., Welch H. G. Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence. New England Journal of Medicine. 367, no. 21 (2012): 1998–2005.
Miller A. B. et al. Twenty Five Year Follow-Up for Breast Cancer Incidence and Mortality of the Canadian National Breast Screening Study: Randomised Screening Trial. British Medical Journal. 348 (2014): 366.
Fagin D. Toms River: A Story of Science and Salvation. Washington, DC: Island Press, 2014.
Ilic D. et al. Prostate Cancer Screening with Prostate-Specific Antigen (PSA) Test: A Systematic Review and Meta-Analysis. BMJ. 362 (2018): k3519.
Loud J., Murphy J. Cancer Screening and Early Detection in the 21st Century. Seminars in Oncology Nursing. 33, no. 2 (2017): 121–128.
Adami H.-O. et al. Towards an Understanding of Breast Cancer Etiology. Seminars in Cancer Biology. 8, no. 4 (1998): 255–262.
Esserman L. J. Overdiagnosis and Overtreatment in Cancer: An Opportunity for Improvement. JAMA. 310, no. 8 (2013): 797.
Autier P., Boniol M. Effect of Screening Mammography on Breast Cancer Incidence. New England Journal of Medicine. 368 (2013): 677–679.
Das S., Batra S. K. Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy. Cancer Research, 2015. doi:10.1158/0008–5472. CAN-15–1050.
Leaf C. The Truth in Small Doses: Why We’re Losing the War on Cancer – And How to Win. New York: Simon & Schuster, 2013.
Adami H.-O. et al. Time to Abandon Early Detection Cancer Screening. European Journal of Clinical Investigation, December 19, 2018. doi:10.1111/eci.13062.
Kopans D. B. Breast Cancer Screening: Where Have We Been and Where Are We Going? A Personal Perspective Based on History, Data and Experience. Clinical Imaging. 48 (2018): vii—xi.
Malvezzi M. et al. European Cancer Mortality Predictions for the Year 2019 with Focus on Breast Cancer. Annals of Oncology, March 19, 2019. doi:10.1093/annonc/mdz051.
Malvezzi M. et al. European Cancer Mortality Predictions for the Year 2018 with Focus on Colorectal Cancer. Annals of Oncology. 29, no. 4 (2018): 1016–1022.
Prasad V. Why Cancer Screening Has Never Been Shown to ‘Save Lives’ – And What We Can Do About It. BMJ. 352 (2016). doi:10.1136/bmj.h6080.
Narod S. A. et al. Why Have Breast Cancer Mortality Rates Declined? Journal of Cancer Policy. 5 (2015): 8–17.
Colantonio S. et al. A Smart Mirror to Promote a Healthy Lifestyle. Biosystems Engineering. 138 (2015): 33–43.
Iverson N. M. et al. In Vivo Biosensing Via Tissue Localizable Near Infrared Fluorescent Single Walled Carbon Nanotubes. Nature Nanotechnology. 8 (2013): 873–880.
Gambhir S. S. Toward Achieving Precision Health. Science Translational Medicine. 10, no. 430 (2018): 3612.
Wong D. Saliva Liquid Biopsy for Cancer Detection. Paper presented at the American Association for the Advancement of Science 2016 Annual Meeting, Washington, DC, February 11–15, 2016.
Johnson J. Intelligent Toilets, Smart Couches and the House of the Future. Financial Post, June 6, 2012. http://business.financialpost.com/uncategorized/intelligent-toilets-smart-couches-and-the-house-of-the-future
Wang L. Microwave Sensors for Breast Cancer Detection. Sensors. 18, no. 2 (2018): 655.
Hsu J. Can a New Smart Bra Really Detect Cancer? Live Science, October 17, 2012.
Kahn N. et al. Dynamic Nanoparticle-Based Flexible Sensors: Diagnosis of Ovarian Carcinoma from Exhaled Breath. Nano Letters. 15, no. 10 (2015): 7023–7028.
Czernin J., Gambhir S. S. Discussions with Leaders: A Conversation Between Sam Gambhir and Johannes Czernin. Journal of Nuclear Medicine. 59, no. 12 (2018): 1783–1785.
Vermesh O. et al. An Intravascular Magnetic Wire for the High-Throughput Retrieval of Circulating Tumour Cells In Vivo. Nature Biomedical Engineering. 2, no. 9 (2018): 696–705.
Ferrari E. et al. Urinary Proteomics Profiles Are Useful for Detection of Cancer Biomarkers and Changes Induced by Therapeutic Procedures. Molecules. 24, no. 4 (2019): 794.
Colditz G. A. et al. Applying What We Know to Accelerate Cancer Prevention. Science Translational Medicine. 4, no. 127 (2012): 127rv4.
Wan J. C. et al. Liquid Biopsies Come of Age: Towards Implementation of Circulating Tumour DNA. Nature Reviews Cancer. 17 (2017): 223–238.
Bianchi D. W. Circulating Fetal DNA: Its Origin and Diagnostic Potential – A Review. Placenta. 25, supplement (2004): S93–S101.
Jahr S. et al. DNA Fragments in the Blood Plasma of Cancer Patients: Quantitations and Evidence for Their Origin from Apoptotic and Necrotic Cells. Cancer Research. 61 (2001): 1659–1665.
Thierry A. R. et al. Clinical Validation of the Detection of KRAS and BRAF Mutations from Circulating Tumor DNA. Nature Medicine. 20 (2014): 430–435.
Ding L. et al. Expanding the Computational Toolbox for Mining Cancer Genomes. Nature Reviews Genetics. 15, no. 8 (2014): 556–570.
Murtaza M. et al. Non-Invasive Analysis of Acquired Resistance to Cancer Therapy by Sequencing of Plasma DNA. Nature. 497 (2013): 108–112.
Siravegna G. et al. Integrating Liquid Biopsies into the Management of Cancer. Nature Reviews Clinical Oncology. 14 (2017): 531–548.
Taylor D. D., Gercel-Taylor C. MicroRNA Signatures of
